Radionuclide therapy of lymphomas

Heather A. Jacene, Sree Harsha Tirumani, Richard L. Wahl

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Radioimmunotherapy is an effective therapy for NHL in a variety of settings and is well tolerated. Current studies continue to investigate the role of NHL at various time points in the management of patients with NHL. The limited clinical use of RIT seems to have been driven by economics rather than by a lack of clinical effectiveness. As new radiolabeled agents and indications and nonradioactive agents are being investigated, probably in parallel with nonradioactive agents, close collaborations between medical oncologists and nuclear medicine physicians/radiologists are paramount for optimal integration of these agents into the overall treatment schema for patients with lymphoma. Radioimmunotherapy (RIT) for treatment of non-Hodgkin lymphoma (NHL) has been undergoing investigations since the early 1990s and became available for clinical use to treat relapsed/refractoryNHL in the early 2000s. Since then, the indications for the use of RIT in NHL have been expanded. RIT for NHL is an effective therapy; however, the use in clinical practice has been limited as there are multiple other competing nonradioactive therapies for NHL, several developed in the past few years. This chapter will provide a review of the current and possible future roles of RIT in patients with lymphoma.

Original languageEnglish
Title of host publicationNuclear Oncology
Subtitle of host publicationFrom Pathophysiology to Clinical Applications
PublisherSpringer International Publishing
Number of pages15
ISBN (Electronic)9783319262369
ISBN (Print)9783319262345
StatePublished - Oct 27 2017


  • Bexxar
  • Lymphoma
  • RIT
  • Radioimmunotherapy
  • Zevalin


Dive into the research topics of 'Radionuclide therapy of lymphomas'. Together they form a unique fingerprint.

Cite this